JLJonathan A. Ledermann

Jonathan A. Ledermann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan A. Ledermann has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.

    by Stephanie M. de Boer, Melanie E. Powell, Linda R. Mileshkin, Dionyssios Katsaros, Paul Bessette, Christine Haie-Meder, Petronella B Ottevanger, Jonathan A. Ledermann, Pearly Khaw, Alessandro Colombo, et al.

    5502 Background: Women with high-risk endometrial cancer (HREC) are at increased risk of distant metastasis and endometrial cancer-related death. The randomized PORTEC-3 intergroup trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (CTRT) versus pelvic radiotherapy (RT) alone for women with HREC. Methods: Women with HREC (FIGO stage I grade 3 with deep myometrial invasion and/or LVSI; stage II or III; or serous/clear cell histology) were randomly allocated (1:1) to RT (48.6 Gy in 1.8 Gy fractions) or CTRT (two cycles of cisplatin 50 mg/m² in week 1 and 4 of RT, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m² at 3-week intervals) with stratification for participating center, lymphadenectomy, stage, and histological type. The co-primary endpoints were overall survival (OS) and failure-free survival (FFS). The Kaplan-Meier method, log-rank test and Cox regression analysis were used for final analysis according to intention-to-treat. PORTEC-3 is registered with ISRCTN (ISRCTN14387080) and ClinicalTrials.gov (NCT00411138). Results: 686 women were enrolled between 2006 and 2013. 26 women were excluded; 13 withdrew consent early and 13 were ineligible, which left 660 patients in the analysis, with a median follow up time of 60.2 months (IQR 47.1–72.9): 330 CTRT and 330 RT. Three- and five-year OS for CTRT vs. RT was 84.4% versus 83.9%, and 81.8% versus 76.7%; overall HR 0.79 [95% CI 0.57-1.12, p=0.183]. Three-year FFS was 79.7% (CTRT) versus 71.8% (RT), and at 5 years 75.5% versus 68.9%, overall HR for FFS 0.77 [0.58-1.03, p=0.078]. Patients with stage III EC had lower 5-year FFS and OS compared to stage I-II (FFS 63.9% vs 78.9%, p


  • Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    by Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, et al.

    (ed from N Engl J Med 2016;375(22):2154–2164) The initial response rate to platinum and taxane treatment in patients with advanced ovarian cancer is high. However, the effectiveness of this regimen diminishes over time, and most patients relapse; with retreatment, relapses occur at shorter intervals until patient death.


  • Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.

    by Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon J. S. Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra, et al.

    5501 Background: In a phase II study (NCT00753545, Study 19), maintenance monotherapy with the EU/US-approved PARP inhibitor olaparib significantly improved PFS, and times to first and second subsequent therapy or death (TFST and TSST), vs placebo in PSR SOC pts. Pts with a BRCA1/2 mutation (BRCAm) derived the greatest benefit from olaparib. Analyses after a data cut-off (DCO) on Nov 26, 2012 did not show a significant OS improvement with olaparib in the full analysis set (FAS) (58% maturity; HR 0.88, 95% CI 0.64–1.21, P =0.44) or BRCAm subgroup (52% maturity; HR 0.73, 95% CI 0.45–1.17, P= 0.19) (Ledermann et al, Lancet Oncol 2014). We report updated OS, evaluated after 77% of pts had died (DCO: Sep 30, 2015). Methods: Pts received olaparib (400 mg bid, capsules) or placebo after response to platinum-based therapy. BRCAm status was known for 254/265 pts (96%) from germline or tumor tests. Results: Maintenance olaparib gave pts an OS advantage vs placebo; analyses suggest that the results seen in the FAS may have been driven by the BRCAm group. Investigations into the contribution of pts who were non-BRCAm buthomologous recombination repair deficient are ongoing. In the FAS, 5-yr survival was 29.2% and 20.4% in the olaparib and placebo arms, respectively (36.9% and 24.3% in BRCAm pts). At the 2015 DCO, 15 pts remained on olaparib (BRCAm, n = 8) and 1 on placebo (BRCAm, n = 1). 18/136 FAS pts (13.2%) received olaparib for > 5 yrs (by subgroup: 11/74 BRCAm pts [14.9%]; 7/62 non-BRCAm pts [11.3%]). There was no change to the safety profile and no new cases of MDS/AML were reported since the 2012 DCO. Conclusions: There is an OS advantage for pts in Study 19 receiving maintenance olaparib after response to platinum therapy. Long-term treatment with maintenance olaparib was observed.This analysis supports prior Study 19 data in pts with BRCAm PSR SOC showing a significant PFS benefit and delay to TFST and TSST with olaparib. Clinical trial information: NCT00753545.


  • TRIOC: A randomised parallel group double-blind phase II study to assess the activity of MVA-5T4 vaccine versus placebo in patients with relapsed asymptomatic epithelial ovarian, fallopian tube, or primary peritoneal cancer.

    by Agnieszka Michael, Rosemary Lord, Geoff Hall, Louise Hanna, Anjana Anand, Axel Walther, Shibani Nicum, Andrew R. Clamp, Rebecca Sophie Kristeleit, Alan Hackshaw, et al.

    TPS5604 Background: Ovarian cancer is the second most common gynaecological malignancy in the Western world. The majority of patients present in an advanced stage and the survival rates are still poor. There is extensive evidence that ovarian cancer is under immune surveillance. Patients who develop CA-125 relapse and do not have clinical symptoms will often have a low volume disease on the CT scan and are ideally suited for immune-based strategies as they do not benefit from chemotherapy. 5T4 is an oncofetal tumour antigen (TAA) which is expressed on the cell surface and has been identified as a promising target for immunotherapy and has high expression in ovarian cancer. Methods: This is a phase II randomised, controlled double-blind multicentre study of a highly attenuated Modified Vaccinia Ankara virus containing the gene encoding for the human TAA, 5T4 (MVA-5T4) in women with relapsed asymptomatic ovarian cancer compared to placebo. The overall aim of the trial is to assess the effectiveness of MVA-5T4 in extending time to progression in asymptomatic relapsed ovarian cancer patients. The primary efficacy endpoint is RECIST-defined progression at 25 weeks. The secondary endpoints include progression free survival defined by immune related response criteria, safety, quality of life, overall survival, immune and exploratory biomarkers. The aim is to detect a progression rate of 50% in the MVA-5T4 arm as compared to 70% in the placebo group. Based on a direct comparison of proportions, 80% power and one-sided test of statistical significance of 20%, the sample size for the study has been set at 75 patients. Patients are randomised to MVA-5T4 or placebo and receive 12 intradermal injections of MVA-5T4, the first 2- once a week followed by injection after 2 weeks, then 3 injections every 3 weeks followed by 6-weekly injections. The inclusion criteria include women who completed cytoreductive surgery and chemotherapy and relapsed with asymptomatic low volume disease detectable on the CT or with CA125 only. 45 out of 75 patients have been recruited. Clinical Trial Information NCT01556841 CR UK endorsed – ref A15045 Clinical trial information: NCT01556841.


    • 1 January 2013
      • Vol. 3

    Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation.

    by Han Hsi Wong, Christine Parkinson, Jonathan A Ledermann, James D Brenton, Michael Merger, Ashley Shaw, Aileen Patterson, Mahmood Shafi, Helena M Earl

  • Top Cited Papers

    Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

    by Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra, et al.

    Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations. We conducted a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen. Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo. The primary end point was progression-free survival according to the Response Evaluation Criteria in Solid Tumors guidelines. Of 265 patients who underwent randomization, 136 were assigned to the olaparib group and 129 to the placebo group. Progression-free survival was significantly longer with olaparib than with placebo (median, 8.4 months vs. 4.8 months from randomization on completion of chemotherapy; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.25 to 0.49; P<0.001). Subgroup analyses of progression-free survival showed that, regardless of subgroup, patients in the olaparib group had a lower risk of progression. Adverse events more commonly reported in the olaparib group than in the placebo group (by more than 10% of patients) were nausea (68% vs. 35%), fatigue (49% vs. 38%), vomiting (32% vs. 14%), and anemia (17% vs. 5%); the majority of adverse events were grade 1 or 2. An interim analysis of overall survival (38% maturity, meaning that 38% of the patients had died) showed no significant difference between groups (hazard ratio with olaparib, 0.94; 95% CI, 0.63 to 1.39; P=0.75). Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer. Interim analysis showed no overall survival benefit. The toxicity profile of olaparib in this population was consistent with that in previous studies. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT00753545.)


  • Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

    by Jonathan A. Ledermann, Allan Hackshaw, Stan Kaye, Gordon Jayson, Hani Gabra, Iain McNeish, Helena Earl, Tim Perren, Martin Gore, Mojca Persic, et al.

    Purpose: Inhibiting angiogenesis is one of the most promising avenues for new therapies for ovarian cancer. We investigated the efficacy and safety of a novel agent, BIBF 1120, a triple angiokinase inhibitor, after chemotherapy for relapsed disease. Patients and Methods: We conducted a randomized, double-blind, controlled phase II trial in 83 patients who had just completed chemotherapy for relapsed ovarian cancer, with evidence of response, but at high risk of further early recurrence. The patients were randomly assigned to receive maintenance therapy using BIBF 1120 250 mg or placebo, twice per day, continuously for 36 weeks. End points were progression-free survival (PFS), toxicity, and overall survival. Results: Thirty-six–week PFS rates were 16.3% and 5.0% in the BIBF 1120 and placebo groups, respectively (hazard ratio, 0.65; 95% CI, 0.42 to 1.02; P = .06). Four patients continued on BIBF 1120, including two patients for another year or more. The proportion of patients with any grade 3 or 4 adverse events was similar between the groups (34.9% for BIBF 1120 v 27.5% for placebo; P = .49; mostly grade 3). However, more patients on BIBF 1120 experienced diarrhea, nausea, or vomiting (mainly grade 1 or 2 and no grade 4). There was a higher rate of grade 3 or 4 hepatotoxicity in patients on BIBF 1120 (51.2%) compared with patients on placebo (7.5%; P < .001), but this was rarely of clinical significance, and patients continued with the trial treatment. A single-level dose reduction to 150 mg was made in 15 patients, all on active drug. Conclusion: BIBF 1120 is well tolerated and associated with a potential improvement in PFS. The observed treatment effect is sufficient to justify further study within a large phase III trial.


  • Open Access

    Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

    by F A Raja, C L Griffin, W Qian, H Hirte, M K Parmar, A M Swart, J A Ledermann

    Cediranib is a potent oral vascular endothelial growth factor (VEGF) signalling inhibitor with activity against all three VEGF receptors. The International Collaboration for Ovarian Neoplasia 6 (ICON6) trial was initiated based on evidence of single-agent activity in ovarian cancer with acceptable toxicity. The ICON6 trial is a 3-arm, 3-stage, double-blind, placebo-controlled randomised trial in first relapse of platinum-sensitive ovarian cancer. Patients are randomised (2 : 3 : 3) to receive six cycles of carboplatin (AUC5/6) plus paclitaxel (175 mg m−2) with either placebo (reference), cediranib 20 mg per day, followed by placebo (concurrent), or cediranib 20 mg per day, followed by cediranib (concurrent plus maintenance). Cediranib or placebo was continued for 18 months or until disease progression. The primary outcome measure for stage I was safety, and the blinded results are presented here. Sixty patients were included in the stage I analysis. A total of 53 patients had received three cycles of chemotherapy and 42 patients had completed six cycles. In all, 19 out of 60 patients discontinued cediranib or placebo during chemotherapy because of adverse events/intercurrent illness (n=9); disease progression (n=1); death (n=3); patient decision (n=1); administrative reasons (n=1); and multiple reasons (n=4). Grade 3 and 4 toxicity was experienced by 30 (50%) and 3 (5%) patients, respectively. No gastrointestinal perforations were observed. The addition of cediranib to platinum-based chemotherapy is sufficiently well tolerated to expand the ICON6 trial and progress to stage II.


  • Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer

    by Jonathan A. Ledermann, Christian Marth, Mark S. Carey, Michael Birrer, David D.L. Bowtell, Stan Kaye, Iain McNeish, Amit Oza, Giovanni Scambia, Gordon Rustin, et al.